Humoral immunoresponse to varicella-zoster virus pernasally coadministered with Escherichia coli enterotoxin in mice

Vaccine

Volumn 18, Issue 19, 2000, Pages 2049-2054

  Tsuji, Takao ^a   Shiraki, Kimiyasu ^b   Sato, Hiroshi ^b   Yue Mea, Jiang ^a   Honma, Yasuko ^a   Yoshikawa, Tetsushi ^a   Asano, Yoshizo ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; ESCHERICHIA COLI ENTEROTOXIN; LIVE VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SERODIAGNOSIS; VARICELLA ZOSTER VIRUS; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACTERIAL TOXINS; DNA PRIMERS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MICE; MICE, INBRED ICR; MOLECULAR WEIGHT; NEUTRALIZATION TESTS; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0034004292     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00487-9     Document Type: Article

References (21)

1. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 2:1974;1288-1290.
2. Asano Y., Suga S., Yoshikawa T., Kobayashi I., Yazaki T,Shibata M., Tsuzuki K., Ito S. Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 94:1994;524-526.
3. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11:1993;1179-1184.
4. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:1992;2277-2281.
5. Tamura S., Asanuma H., Tomita T., Komase K., Kawahara K., Danbara H., Hattori N., Watanabe K., Suzuki Y., Nagamine T., et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:1994;1083-1089.
6. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1995;1617-1623.
7. Tsuji T., Yokochi T., Kamiya H., Kawamoto Y., Miyama A., Asano Y. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology. 90:1997;176-182.
8. Kato M., Imamura S., Kawase H., Miyama A., Tsuji T. Histidine-44 of the A subunit of Escherichia coli enterotoxin is involved in its enzymatic and biological activities. FEMS Microbiol. Lett. 152:1997;219-225.
9. Tsuji T., Kato M., Kawase H., Imamura S., Kamiya H., Ichinose Y., Miyama A. Escherichia coli LT enterotoxin subunit A demonstrates partial toxicity independent of the nicking around Arg192. Microbiology. 143:1997;1797-1804.
10. Asano Y., Albrecht P., Vujcic L.K., Quinnan G.V. Jr, Kawakami K., Takahashi M. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics. 72:1983;291-294.
11. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
12. Matsui S., Okuno T., Shiraki K. Functional roles of terminal glycomoieties in Varicella-Zoster virus infection. Virology. 198:1994;50-58.
13. Shiraki K., Sato H., Yamamura J., Li Z.H., Yokoyama T., Hasegawa T., Okuno T., Kurokawa M., Kageyama S. Functions of purified gB, gE:gI, and gH:gL, and their sialyl residues in varicella-zoster virus function. Arch. Virol. 142:1997;2295-2301.
14. Tsuji T., Inoue T., Miyama A., Okamoto K., Honda T., Miwatani T. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity. J. Biol. Chem. 265:1990;22520-22525.
15. Davison A.J., Edson C.M., Ellis R.W., Forghani B., Gilden D., Grose C., Keller P.M., Vafai A., Wroblewska Z., Yamanishi K. New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J. Viroll. 57:1986;1195-1197.
16. Jacquet A., Massaer M., Haumont M., Houard S., Deleersnyder V., Place M., Bollen A., Jacobs P. Purification and characterization of recombinant varicella-zoster virus glycoprotein gpII, secreted by Chinese hamster ovary cells. Prot. Exp. Purif. 6:1995;91-98.
17. Davies J., Hallworth J.A., McLeish P., Randall S., Martin B.A., Buchan A., Skinner G.R. Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Med. Microbiol. Immunl. 183:1994;105-117.
18. Vafai A. Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine. 11:1993;937-940.
19. Vafai A., Yang W.N. Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV. J. Virol. 65:1991;5593-5596.
20. Myers M.G., Connelly B.L. Animal models of varicella. J. Infect. Dis. 166:1992;S48-S50.
21. Sun J.B., Rask C., Olsson T., Holmgren J., Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA. 93:1996;7196-7201.